Key result
Heparin prevents acute thrombosis during PCI with cost and reversibility advantages over bivalirudin.
Why the study?
Optimal heparin dosing regimens and their efficacy compared with other anticoagulants such as bivalirudin in PCI remain debated.
This review highlights the ongoing debate regarding optimal heparin dosing and its comparative efficacy against bivalirudin in minimizing thrombotic and bleeding risks during PCI.
Answers are grounded in this paper and cite their sources.
Heparin's reversibility and cost sustain its PCI role; review leaves optimal dosing and bivalirudin comparisons open for prospective trials.
Heparin is stored endogenously within the secretory granules of basophils and mast cells, and is only released into the vasculature at sites of injury. At these sites, it helps maintain proper blood flow by balancing the active anticoagulant and procoagulant processes. Pharmaceutical-grade heparin is derived from animal tissue, but one form is made synthetically. Heparin is commonly used in the management of coronary artery disease, deep vein thrombosis, pulmonary embolism, and atrial fibrillation, and in the prevention of thrombosis during cardiopulmonary bypass and extracorporeal membrane oxygenation. Heparin treatment is a key component in elective percutaneous coronary intervention (PCI). It plays an important role in minimizing the risk of thrombotic events during PCI and is one of the most popular anticoagulants used. However, some studies show that higher heparin doses are associated with more frequent bleeding complications, which can increase morbidity and mortality. The optimal heparin dosing regimens are still debated, as well as their efficacy in PCI compared with that of other drugs such as bivalirudin. This review examines the physiology, pharmacology, therapeutic applications, dosing regimens, and efficacy of heparin in the setting of PCI. In addition, included is a review of data on addition of glycoprotein IIb/IIIa inhibitors to heparin and comparison of heparin monotherapy to bivalirudin in PCI.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2015) conducted a review in Percutaneous coronary intervention (PCI). Heparin vs. Bivalirudin was evaluated. Heparin plays a critical role in preventing acute thrombotic events during percutaneous coronary intervention, offering advantages in reversibility and cost compared to bivalirudin, though optimal dosing regimens remain debated.
Synapse has enriched 10 related papers. Consider them for comparative context: